US20190343836A1 - Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor - Google Patents
Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor Download PDFInfo
- Publication number
- US20190343836A1 US20190343836A1 US16/475,982 US201816475982A US2019343836A1 US 20190343836 A1 US20190343836 A1 US 20190343836A1 US 201816475982 A US201816475982 A US 201816475982A US 2019343836 A1 US2019343836 A1 US 2019343836A1
- Authority
- US
- United States
- Prior art keywords
- amino
- methyl
- decan
- azaspiro
- thio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- HNMVMRPKJOFPLS-GDCHUWMGSA-N C#CC1=CC2=C(C=C1)C1=C(N2)C(C)(C)C2=CC(N3CCC(N4CCOCC4)CC3)=C(CC)C=C2C1=O.C=S(=O)(C1=CC=CC=C1CC1=NC=NC(CC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C=C2OC)=N1)C(C)C.COC1=C(CC2=NC(NC3=C(S(=O)(=O)C(C)C)C=CC=C3)=C(C)C=N2)C=CC(N2CCC(N3CCN(C)CC3)CC2)=C1.COC1=CC(N2CCC(N(C)C)CC2)=CC=C1CC1=NC=C(Cl)C(CC2=CC=CC=C2P(C)(C)=O)=N1.C[C@@H](OC1=CC(C2=CN(C3CCNCC3)N=C2)=CN=C1N)C1=C(Cl)C=CC(F)=C1Cl Chemical compound C#CC1=CC2=C(C=C1)C1=C(N2)C(C)(C)C2=CC(N3CCC(N4CCOCC4)CC3)=C(CC)C=C2C1=O.C=S(=O)(C1=CC=CC=C1CC1=NC=NC(CC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C=C2OC)=N1)C(C)C.COC1=C(CC2=NC(NC3=C(S(=O)(=O)C(C)C)C=CC=C3)=C(C)C=N2)C=CC(N2CCC(N3CCN(C)CC3)CC2)=C1.COC1=CC(N2CCC(N(C)C)CC2)=CC=C1CC1=NC=C(Cl)C(CC2=CC=CC=C2P(C)(C)=O)=N1.C[C@@H](OC1=CC(C2=CN(C3CCNCC3)N=C2)=CN=C1N)C1=C(Cl)C=CC(F)=C1Cl HNMVMRPKJOFPLS-GDCHUWMGSA-N 0.000 description 3
- AWCUGJTVKPBYHS-CQSZACIVSA-N CN1C(=O)C2=C(\C3=C(Cl)C(Cl)=CC=C3)N/N=C\2N=C1N1CCC2(CCC[C@H]2N)CC1 Chemical compound CN1C(=O)C2=C(\C3=C(Cl)C(Cl)=CC=C3)N/N=C\2N=C1N1CCC2(CCC[C@H]2N)CC1 AWCUGJTVKPBYHS-CQSZACIVSA-N 0.000 description 2
- VRVGEMSOLWLSKN-UHFFFAOYSA-N COC1=C(NC2=NC=C(Cl)C(C3=CCC4=CC=CC=C43)=N2)C=CC(N2CCC(C)CC2)=C1 Chemical compound COC1=C(NC2=NC=C(Cl)C(C3=CCC4=CC=CC=C43)=N2)C=CC(N2CCC(C)CC2)=C1 VRVGEMSOLWLSKN-UHFFFAOYSA-N 0.000 description 2
- IKKUGOCAYJSNOZ-XJKSGUPXSA-N C[C@H]1C[C@@H](N)C2(CCN(C3=NC(N)=C(C4=CC=C(Cl)C=C4)C(=O)N3C)CC2)C1 Chemical compound C[C@H]1C[C@@H](N)C2(CCN(C3=NC(N)=C(C4=CC=C(Cl)C=C4)C(=O)N3C)CC2)C1 IKKUGOCAYJSNOZ-XJKSGUPXSA-N 0.000 description 2
- GHNNUZAENHZAOE-SWLSCSKDSA-N C[C@H]1C[C@@H](N)C2(CCN(C3=NC(N)=C(SC4=CC=NC=C4C(F)(F)F)C(=O)N3C)CC2)C1 Chemical compound C[C@H]1C[C@@H](N)C2(CCN(C3=NC(N)=C(SC4=CC=NC=C4C(F)(F)F)C(=O)N3C)CC2)C1 GHNNUZAENHZAOE-SWLSCSKDSA-N 0.000 description 2
- VCACXGULTWUFOL-CMPLNLGQSA-N NC1=C(SC2=C(Cl)C(Cl)=NC=C2)N=CC(N2CCC3(CC2)C[C@@H](O)C[C@H]3N)=N1 Chemical compound NC1=C(SC2=C(Cl)C(Cl)=NC=C2)N=CC(N2CCC3(CC2)C[C@@H](O)C[C@H]3N)=N1 VCACXGULTWUFOL-CMPLNLGQSA-N 0.000 description 2
- OMJHHTRDBKAMSN-LLVKDONJSA-N NC1=NC=CC(SC2=C(N)N=C(N3CCC4(CC3)COC[C@H]4N)C=N2)=C1Cl Chemical compound NC1=NC=CC(SC2=C(N)N=C(N3CCC4(CC3)COC[C@H]4N)C=N2)=C1Cl OMJHHTRDBKAMSN-LLVKDONJSA-N 0.000 description 2
- YFMXXMJLAJOQKJ-UHFFFAOYSA-N NCC1(C2=CC=CC=C2)CCN(C2=CN=C(C3=C(Cl)C(Cl)=CC=C3)C(N)=N2)CC1 Chemical compound NCC1(C2=CC=CC=C2)CCN(C2=CN=C(C3=C(Cl)C(Cl)=CC=C3)C(N)=N2)CC1 YFMXXMJLAJOQKJ-UHFFFAOYSA-N 0.000 description 2
- VPKCUGLGCPHVAI-UHFFFAOYSA-N CC1(CC(=O)OC(C)(C)C)CCN(C2=NC(N)=C(SC3=CC=CC(N)=C3Cl)N=C2)CC1.CC1(N)CCN(C2=NC(N)=C(SC3=CC=CC(CC(=O)C4=C(O)N=C5C=CC=CN5C4=O)=C3Cl)N=C2)CC1.CC1(NC(=O)OC(C)(C)C)CCNCC1.COC(=O)C1=C(O)N=C2C=CC=CN2C1=O.NC1=C(Cl)C(S)=CC=C1.NC1=NC(Cl)=CN=C1Br.NC1=NC(Cl)=CN=C1SC1=CC=CC(N)=C1Cl Chemical compound CC1(CC(=O)OC(C)(C)C)CCN(C2=NC(N)=C(SC3=CC=CC(N)=C3Cl)N=C2)CC1.CC1(N)CCN(C2=NC(N)=C(SC3=CC=CC(CC(=O)C4=C(O)N=C5C=CC=CN5C4=O)=C3Cl)N=C2)CC1.CC1(NC(=O)OC(C)(C)C)CCNCC1.COC(=O)C1=C(O)N=C2C=CC=CN2C1=O.NC1=C(Cl)C(S)=CC=C1.NC1=NC(Cl)=CN=C1Br.NC1=NC(Cl)=CN=C1SC1=CC=CC(N)=C1Cl VPKCUGLGCPHVAI-UHFFFAOYSA-N 0.000 description 1
- ZAMNYDQBNJFTSZ-UHFFFAOYSA-N CC1(CN)CCN(C2=CN=C(C3=C(Cl)C(Cl)=CC=C3)C(N)=N2)CC1 Chemical compound CC1(CN)CCN(C2=CN=C(C3=C(Cl)C(Cl)=CC=C3)C(N)=N2)CC1 ZAMNYDQBNJFTSZ-UHFFFAOYSA-N 0.000 description 1
- JBLYMVJAFCDNOA-UHFFFAOYSA-N CC1(CN)CCN(C2=NC(N)=C(SC3=C(C(F)(F)F)N=CC=C3)N=C2)CC1 Chemical compound CC1(CN)CCN(C2=NC(N)=C(SC3=C(C(F)(F)F)N=CC=C3)N=C2)CC1 JBLYMVJAFCDNOA-UHFFFAOYSA-N 0.000 description 1
- SXLOCFFGRYJKJH-UHFFFAOYSA-N CC1(CN)CCN(C2=NC(N)=C(SC3=CC=CC(NC(=O)/C4=C(O)/N=C5/C=CC=CN5C4=O)=C3Cl)N=C2)CC1 Chemical compound CC1(CN)CCN(C2=NC(N)=C(SC3=CC=CC(NC(=O)/C4=C(O)/N=C5/C=CC=CN5C4=O)=C3Cl)N=C2)CC1 SXLOCFFGRYJKJH-UHFFFAOYSA-N 0.000 description 1
- NYPXMXPABWAYNI-UHFFFAOYSA-N CC1(CN)CCN(C2=NC(N)=C(SC3=CC=CC(NC(=O)/C4=C(O)/N=C5/CCCCN5C4=O)=C3Cl)N=C2)CC1 Chemical compound CC1(CN)CCN(C2=NC(N)=C(SC3=CC=CC(NC(=O)/C4=C(O)/N=C5/CCCCN5C4=O)=C3Cl)N=C2)CC1 NYPXMXPABWAYNI-UHFFFAOYSA-N 0.000 description 1
- LBHVOFTWPJBUBW-UHFFFAOYSA-N CC1(CN)CCN(C2=NC3=C(C(=O)N2)/C(C2=C(Cl)C(Cl)=CC=C2)=C\C3)CC1 Chemical compound CC1(CN)CCN(C2=NC3=C(C(=O)N2)/C(C2=C(Cl)C(Cl)=CC=C2)=C\C3)CC1 LBHVOFTWPJBUBW-UHFFFAOYSA-N 0.000 description 1
- YGUFCDOEKKVKJK-UHFFFAOYSA-N CC1(N)CCN(C2=NC(N)=C(C3=CC=CC(Cl)=C3Cl)N=C2)CC1 Chemical compound CC1(N)CCN(C2=NC(N)=C(C3=CC=CC(Cl)=C3Cl)N=C2)CC1 YGUFCDOEKKVKJK-UHFFFAOYSA-N 0.000 description 1
- JZDGMMPURNKFOD-UHFFFAOYSA-N CC1(N)CCN(C2=NC(N)=C(SC3=CC=CC(NC(=O)/C4=C(O)/N=C5/C=CC=CN5C4=O)=C3Cl)N=C2)CC1 Chemical compound CC1(N)CCN(C2=NC(N)=C(SC3=CC=CC(NC(=O)/C4=C(O)/N=C5/C=CC=CN5C4=O)=C3Cl)N=C2)CC1 JZDGMMPURNKFOD-UHFFFAOYSA-N 0.000 description 1
- JBTYRLRPDPSWAY-UHFFFAOYSA-N CC1(N)CCN(C2=NC(N)=C(SC3=CC=CC(NC(=O)C4=C(O)CN(C5=CC=CC=C5)C4=O)=C3Cl)N=C2)CC1 Chemical compound CC1(N)CCN(C2=NC(N)=C(SC3=CC=CC(NC(=O)C4=C(O)CN(C5=CC=CC=C5)C4=O)=C3Cl)N=C2)CC1 JBTYRLRPDPSWAY-UHFFFAOYSA-N 0.000 description 1
- JLWLVSCZOWTUQJ-CYBMUJFWSA-N CC1=C(C2=C3C(=O)N(C)C(N4CCC5(CC4)CC(F)(F)C[C@H]5N)=NC3=NN2)C=CC(N)=N1 Chemical compound CC1=C(C2=C3C(=O)N(C)C(N4CCC5(CC4)CC(F)(F)C[C@H]5N)=NC3=NN2)C=CC(N)=N1 JLWLVSCZOWTUQJ-CYBMUJFWSA-N 0.000 description 1
- PXWVEUAMAFDBCT-SWLSCSKDSA-N CC1=C(C2=C3C(=O)N(C)C(N4CCC5(CC4)C[C@@H](C)C[C@H]5N)=NC3=NN2)C=CC(N)=N1 Chemical compound CC1=C(C2=C3C(=O)N(C)C(N4CCC5(CC4)C[C@@H](C)C[C@H]5N)=NC3=NN2)C=CC(N)=N1 PXWVEUAMAFDBCT-SWLSCSKDSA-N 0.000 description 1
- WBLVYPQDIVMRPP-UHFFFAOYSA-N CC1=C(C2CCCCC2)C=C(OC(C)C)C(NC2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)=C1 Chemical compound CC1=C(C2CCCCC2)C=C(OC(C)C)C(NC2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)=C1 WBLVYPQDIVMRPP-UHFFFAOYSA-N 0.000 description 1
- PMWMMYBAECEPMB-BLLLJJGKSA-N CC1=C(Cl)C(SC2=C(N)N=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N(C)C2=O)=CC=N1 Chemical compound CC1=C(Cl)C(SC2=C(N)N=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N(C)C2=O)=CC=N1 PMWMMYBAECEPMB-BLLLJJGKSA-N 0.000 description 1
- DIFDDGZESHEIPC-JOPIAHFSSA-N CC1CCC2(CCN(C3=NC(N)=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2)[C@@H]1N Chemical compound CC1CCC2(CCN(C3=NC(N)=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2)[C@@H]1N DIFDDGZESHEIPC-JOPIAHFSSA-N 0.000 description 1
- OVNZJLIYRSOHHB-RGUGMKFQSA-N CC1CCC2(CCN(C3=NC=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2)[C@@H]1N Chemical compound CC1CCC2(CCN(C3=NC=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2)[C@@H]1N OVNZJLIYRSOHHB-RGUGMKFQSA-N 0.000 description 1
- BSPKRXNBXSLYTO-XHDPSFHLSA-N CC[C@@H]1OCC2(CCN(C3=NC(N)=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2)[C@@H]1N Chemical compound CC[C@@H]1OCC2(CCN(C3=NC(N)=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2)[C@@H]1N BSPKRXNBXSLYTO-XHDPSFHLSA-N 0.000 description 1
- NQCUFBIRMAZNJZ-SWLSCSKDSA-N CC[C@@H]1OCC2(CCN(C3=NC(N)=C(SC4=CC=CN=C4C(F)(F)F)C(=O)N3C)CC2)[C@@H]1N Chemical compound CC[C@@H]1OCC2(CCN(C3=NC(N)=C(SC4=CC=CN=C4C(F)(F)F)C(=O)N3C)CC2)[C@@H]1N NQCUFBIRMAZNJZ-SWLSCSKDSA-N 0.000 description 1
- JJTYMCPMKUFMGA-UHFFFAOYSA-N CN1C(=O)C(C(=O)NC2=C(Cl)C(SC3=C(N)N=C(N4CCC(C)(N)CC4)C=N3)=CC=C2)=C(O)C1CC1=CC=CC=C1 Chemical compound CN1C(=O)C(C(=O)NC2=C(Cl)C(SC3=C(N)N=C(N4CCC(C)(N)CC4)C=N3)=CC=C2)=C(O)C1CC1=CC=CC=C1 JJTYMCPMKUFMGA-UHFFFAOYSA-N 0.000 description 1
- OOZUDBICHRCGIM-LLVKDONJSA-N CN1C(=O)C(SC2=CC=NC(N)=C2Cl)=C(N)N=C1N1CCC2(CC1)CC(F)(F)C[C@H]2N Chemical compound CN1C(=O)C(SC2=CC=NC(N)=C2Cl)=C(N)N=C1N1CCC2(CC1)CC(F)(F)C[C@H]2N OOZUDBICHRCGIM-LLVKDONJSA-N 0.000 description 1
- YQIKHFKYMKSZMC-YVEFUNNKSA-N COC1=C(Cl)C(SC2=C(N)N=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N(C)C2=O)=CC=C1 Chemical compound COC1=C(Cl)C(SC2=C(N)N=C(N3CCC4(CC3)CO[C@@H](C)[C@H]4N)N(C)C2=O)=CC=C1 YQIKHFKYMKSZMC-YVEFUNNKSA-N 0.000 description 1
- KAJFXTBNFWMLBS-UHFFFAOYSA-N COC1=C(NC2=NC=C(Cl)C(C3=CCC4=CC=CC=C43)=N2)C=CC(N2CCC(N)CC2)=C1 Chemical compound COC1=C(NC2=NC=C(Cl)C(C3=CCC4=CC=CC=C43)=N2)C=CC(N2CCC(N)CC2)=C1 KAJFXTBNFWMLBS-UHFFFAOYSA-N 0.000 description 1
- GPLJNNPTBMEPKG-ORAYPTAESA-N COC1=NC=CC(C2=CCC3=C2C(=O)N(C)C(N2CCC4(CC2)CO[C@@H](C)[C@H]4N)=N3)=C1Cl Chemical compound COC1=NC=CC(C2=CCC3=C2C(=O)N(C)C(N2CCC4(CC2)CO[C@@H](C)[C@H]4N)=N3)=C1Cl GPLJNNPTBMEPKG-ORAYPTAESA-N 0.000 description 1
- MQHUNAGZKZJLQU-APPDUMDISA-N C[C@@H]1OCC2(CCN(C3=NC(N)=C(C4=C(Cl)C(Cl)=CC=C4)N=C3)CC2)[C@@H]1N Chemical compound C[C@@H]1OCC2(CCN(C3=NC(N)=C(C4=C(Cl)C(Cl)=CC=C4)N=C3)CC2)[C@@H]1N MQHUNAGZKZJLQU-APPDUMDISA-N 0.000 description 1
- UCJZOKGUEJUNIO-IINYFYTJSA-N C[C@@H]1OCC2(CCN(C3=NC(N)=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2)[C@@H]1N Chemical compound C[C@@H]1OCC2(CCN(C3=NC(N)=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2)[C@@H]1N UCJZOKGUEJUNIO-IINYFYTJSA-N 0.000 description 1
- YDOIDJXVWAVDGD-MEDUHNTESA-N C[C@@H]1OCC2(CCN(C3=NC(N)=C(SC4=CC=CC(Cl)=C4Cl)C(=O)N3C)CC2)[C@@H]1N Chemical compound C[C@@H]1OCC2(CCN(C3=NC(N)=C(SC4=CC=CC(Cl)=C4Cl)C(=O)N3C)CC2)[C@@H]1N YDOIDJXVWAVDGD-MEDUHNTESA-N 0.000 description 1
- FWLRJXKKWWAIIU-MEDUHNTESA-N C[C@@H]1OCC2(CCN(C3=NC(N)=C(SC4=CC=CC(N)=C4C(F)(F)F)C(=O)N3C)CC2)[C@@H]1N Chemical compound C[C@@H]1OCC2(CCN(C3=NC(N)=C(SC4=CC=CC(N)=C4C(F)(F)F)C(=O)N3C)CC2)[C@@H]1N FWLRJXKKWWAIIU-MEDUHNTESA-N 0.000 description 1
- NGJFCIYVFFUILZ-OYHNWAKOSA-N C[C@@H]1OCC2(CCN(C3=NC(N)=C(SC4=CC=CC(NC(=O)/C5=C(O)/N=C6/CCCCN6C5=O)=C4Cl)N=C3)CC2)[C@@H]1N Chemical compound C[C@@H]1OCC2(CCN(C3=NC(N)=C(SC4=CC=CC(NC(=O)/C5=C(O)/N=C6/CCCCN6C5=O)=C4Cl)N=C3)CC2)[C@@H]1N NGJFCIYVFFUILZ-OYHNWAKOSA-N 0.000 description 1
- QZHZIDHAIVAHMD-SMDDNHRTSA-N C[C@@H]1OCC2(CCN(C3=NC(N)=C(SC4=CC=CN=C4C(F)(F)F)C(=O)N3C)CC2)[C@@H]1N Chemical compound C[C@@H]1OCC2(CCN(C3=NC(N)=C(SC4=CC=CN=C4C(F)(F)F)C(=O)N3C)CC2)[C@@H]1N QZHZIDHAIVAHMD-SMDDNHRTSA-N 0.000 description 1
- DEBVNDHNGLRJKA-XHDPSFHLSA-N C[C@@H]1OCC2(CCN(C3=NC(N)=C(SC4=CC=NC=C4C(F)(F)F)C(=O)N3C)CC2)[C@@H]1N Chemical compound C[C@@H]1OCC2(CCN(C3=NC(N)=C(SC4=CC=NC=C4C(F)(F)F)C(=O)N3C)CC2)[C@@H]1N DEBVNDHNGLRJKA-XHDPSFHLSA-N 0.000 description 1
- FDSVUVZQRZMZJD-MGPLVRAMSA-N C[C@@H]1OCC2(CCN(C3=NC4=C(N=C3)C(C3=C(Cl)C(Cl)=NC=C3)=NN4)CC2)[C@@H]1N Chemical compound C[C@@H]1OCC2(CCN(C3=NC4=C(N=C3)C(C3=C(Cl)C(Cl)=NC=C3)=NN4)CC2)[C@@H]1N FDSVUVZQRZMZJD-MGPLVRAMSA-N 0.000 description 1
- PAWWJOLMHYVYQE-RNODOKPDSA-N C[C@@H]1OCC2(CCN(C3=NC4=N/N/C(C5=C(Cl)C(CC6CC6)=NC=C5)=C\4C(=O)N3C)CC2)[C@@H]1N Chemical compound C[C@@H]1OCC2(CCN(C3=NC4=N/N/C(C5=C(Cl)C(CC6CC6)=NC=C5)=C\4C(=O)N3C)CC2)[C@@H]1N PAWWJOLMHYVYQE-RNODOKPDSA-N 0.000 description 1
- ZGMUIFZUVXWGJL-MGPLVRAMSA-N C[C@@H]1OCC2(CCN(C3=NC=C(SC4=C(Cl)C(Cl)=NC(N)=C4)N=C3)CC2)[C@@H]1N Chemical compound C[C@@H]1OCC2(CCN(C3=NC=C(SC4=C(Cl)C(Cl)=NC(N)=C4)N=C3)CC2)[C@@H]1N ZGMUIFZUVXWGJL-MGPLVRAMSA-N 0.000 description 1
- NIQAQDPFKXLLSZ-MEDUHNTESA-N C[C@@H]1OCC2(CCN(C3=NC=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2)[C@@H]1N Chemical compound C[C@@H]1OCC2(CCN(C3=NC=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2)[C@@H]1N NIQAQDPFKXLLSZ-MEDUHNTESA-N 0.000 description 1
- LNQYLYAZNKGMBQ-GOEBONIOSA-N C[C@H]1C[C@@H](N)C2(CCN(C3=NC(N)=C(C4=CC=CC=C4)C(=O)N3C)CC2)C1 Chemical compound C[C@H]1C[C@@H](N)C2(CCN(C3=NC(N)=C(C4=CC=CC=C4)C(=O)N3C)CC2)C1 LNQYLYAZNKGMBQ-GOEBONIOSA-N 0.000 description 1
- QRCMRHHVLLNDAD-WCQYABFASA-N C[C@H]1C[C@@H](N)C2(CCN(C3=NC(N)=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2)C1 Chemical compound C[C@H]1C[C@@H](N)C2(CCN(C3=NC(N)=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2)C1 QRCMRHHVLLNDAD-WCQYABFASA-N 0.000 description 1
- FKPNMVUOIGQWCP-BLLLJJGKSA-N C[C@H]1C[C@@H](N)C2(CCN(C3=NC(N)=C(SC4=CC(Cl)=C(Cl)C=C4)C(=O)N3C)CC2)C1 Chemical compound C[C@H]1C[C@@H](N)C2(CCN(C3=NC(N)=C(SC4=CC(Cl)=C(Cl)C=C4)C(=O)N3C)CC2)C1 FKPNMVUOIGQWCP-BLLLJJGKSA-N 0.000 description 1
- XDODTCSHMOQQKP-GXTWGEPZSA-N C[C@H]1C[C@@H](N)C2(CCN(C3=NC=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2)C1 Chemical compound C[C@H]1C[C@@H](N)C2(CCN(C3=NC=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2)C1 XDODTCSHMOQQKP-GXTWGEPZSA-N 0.000 description 1
- MLZSINIGJFDNQZ-UHFFFAOYSA-N NC1=C(C2=C(Cl)C(Cl)=CC=C2)N=CC(N2CCC3(CCCN3)CC2)=N1 Chemical compound NC1=C(C2=C(Cl)C(Cl)=CC=C2)N=CC(N2CCC3(CCCN3)CC2)=N1 MLZSINIGJFDNQZ-UHFFFAOYSA-N 0.000 description 1
- DYZZCXHBYCBNEC-CQSZACIVSA-N NC1=C(C2=C(Cl)C(Cl)=CC=C2)N=CC(N2CCC3(CCC[C@H]3N)CC2)=N1 Chemical compound NC1=C(C2=C(Cl)C(Cl)=CC=C2)N=CC(N2CCC3(CCC[C@H]3N)CC2)=N1 DYZZCXHBYCBNEC-CQSZACIVSA-N 0.000 description 1
- HRZBBEFONKKGFY-GFCCVEGCSA-N NC1=C(SC2=C(C(F)(F)F)N=CC=C2)N=CC(N2CCC3(CC2)COC[C@H]3N)=N1 Chemical compound NC1=C(SC2=C(C(F)(F)F)N=CC=C2)N=CC(N2CCC3(CC2)COC[C@H]3N)=N1 HRZBBEFONKKGFY-GFCCVEGCSA-N 0.000 description 1
- ILINPAZQNCUDMW-CYBMUJFWSA-N NC1=C(SC2=C(C(F)(F)F)N=CC=C2)N=CC(N2CCC3(CCC[C@H]3N)CC2)=N1 Chemical compound NC1=C(SC2=C(C(F)(F)F)N=CC=C2)N=CC(N2CCC3(CCC[C@H]3N)CC2)=N1 ILINPAZQNCUDMW-CYBMUJFWSA-N 0.000 description 1
- VCACXGULTWUFOL-ZYHUDNBSSA-N NC1=C(SC2=C(Cl)C(Cl)=NC=C2)N=CC(N2CCC3(CC2)C[C@H](O)C[C@H]3N)=N1 Chemical compound NC1=C(SC2=C(Cl)C(Cl)=NC=C2)N=CC(N2CCC3(CC2)C[C@H](O)C[C@H]3N)=N1 VCACXGULTWUFOL-ZYHUDNBSSA-N 0.000 description 1
- PVBNSTQJFPASQY-QGZVFWFLSA-N NC1=C(SC2=C(Cl)C(NC(=O)/C3=C(O)/N=C4/CCCCN4C3=O)=CC=C2)N=CC(N2CCC3(CC2)CC(F)(F)C[C@H]3N)=N1 Chemical compound NC1=C(SC2=C(Cl)C(NC(=O)/C3=C(O)/N=C4/CCCCN4C3=O)=CC=C2)N=CC(N2CCC3(CC2)CC(F)(F)C[C@H]3N)=N1 PVBNSTQJFPASQY-QGZVFWFLSA-N 0.000 description 1
- ZVBSVBHUEYAOGL-UHFFFAOYSA-N NC1=C(SC2=CC=CC(NC(=O)/C3=C(O)/N=C4/C=CC=CN4C3=O)=C2Cl)N=CC(N2CCC(N)(CF)CC2)=N1 Chemical compound NC1=C(SC2=CC=CC(NC(=O)/C3=C(O)/N=C4/C=CC=CN4C3=O)=C2Cl)N=CC(N2CCC(N)(CF)CC2)=N1 ZVBSVBHUEYAOGL-UHFFFAOYSA-N 0.000 description 1
- QQGWBWWGXPNCEH-UHFFFAOYSA-N NC1=C(SC2=CC=CC(NC(=O)/C3=C(O)/N=C4/CCCCN4C3=O)=C2Cl)N=CC(N2CCC(N)(CF)CC2)=N1 Chemical compound NC1=C(SC2=CC=CC(NC(=O)/C3=C(O)/N=C4/CCCCN4C3=O)=C2Cl)N=CC(N2CCC(N)(CF)CC2)=N1 QQGWBWWGXPNCEH-UHFFFAOYSA-N 0.000 description 1
- SJVCCJDLEIGCAW-QGZVFWFLSA-N NC1=C(SC2=CC=CC(NC(=O)/C3=C(O)/N=C4/CCCCN4C3=O)=C2Cl)N=CC(N2CCC3(CC2)COC[C@H]3N)=N1 Chemical compound NC1=C(SC2=CC=CC(NC(=O)/C3=C(O)/N=C4/CCCCN4C3=O)=C2Cl)N=CC(N2CCC3(CC2)COC[C@H]3N)=N1 SJVCCJDLEIGCAW-QGZVFWFLSA-N 0.000 description 1
- QZVSNMBRLYUYQI-GOSISDBHSA-N NC1=C(SC2=CC=CC(NC(=O)/C3=C(O)/N=C4/CCCCN4C3=O)=C2Cl)N=CC(N2CCC3(CCC[C@H]3N)CC2)=N1 Chemical compound NC1=C(SC2=CC=CC(NC(=O)/C3=C(O)/N=C4/CCCCN4C3=O)=C2Cl)N=CC(N2CCC3(CCC[C@H]3N)CC2)=N1 QZVSNMBRLYUYQI-GOSISDBHSA-N 0.000 description 1
- YXXCYOPEUVHPLV-GFCCVEGCSA-N NC1=NC=CC(SC2=C(N)N=C(N3CCC4(CCC[C@H]4N)CC3)C=N2)=C1Cl Chemical compound NC1=NC=CC(SC2=C(N)N=C(N3CCC4(CCC[C@H]4N)CC3)C=N2)=C1Cl YXXCYOPEUVHPLV-GFCCVEGCSA-N 0.000 description 1
- AHSZEDCSMMKDNF-GFCCVEGCSA-N NC1=NC=CC(SC2=CN=C(N3CCC4(CC3)COC[C@H]4N)C=N2)=C1Cl Chemical compound NC1=NC=CC(SC2=CN=C(N3CCC4(CC3)COC[C@H]4N)C=N2)=C1Cl AHSZEDCSMMKDNF-GFCCVEGCSA-N 0.000 description 1
- VPCWGBLXOCIIMU-WCQYABFASA-N NC1=NC=CC(SC2=CN=C(N3CCC4(CC3)C[C@@H](O)C[C@H]4N)C=N2)=C1Cl Chemical compound NC1=NC=CC(SC2=CN=C(N3CCC4(CC3)C[C@@H](O)C[C@H]4N)C=N2)=C1Cl VPCWGBLXOCIIMU-WCQYABFASA-N 0.000 description 1
- CQASZSQCUYWGME-CYBMUJFWSA-N NC1=NC=CC(SC2=CN=C(N3CCC4(CCC[C@H]4N)CC3)C=N2)=C1Cl Chemical compound NC1=NC=CC(SC2=CN=C(N3CCC4(CCC[C@H]4N)CC3)C=N2)=C1Cl CQASZSQCUYWGME-CYBMUJFWSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- FIG. 2 Plot of the growth inhibition of MGH049 tumor model with ceritinb, Compound No. 1, or the combination of ceritinib and Compound No. 1.
- the MGH049 cell line was implanted into the flanks of nude mice. Animals were randomized into 4 groups when the average tumor volume was 200-300 mm 3 and received vehicle, ceritinib (20 mg/kg), Compound No. 1 (75 mg/kg) or both inhibitors in combination. Tumor dimensions and body weights were measured at the time of randomization and twice weekly thereafter for the study duration. Average tumor volume and SEM are shown as a function of time. Data shows the combination of ceritinib and Compound No. 1 is more effective in the inhibition of tumor growth than either compound alone in vivo.
- the ALK inhibitor can be for example a compound selected from the group consisting of 5-chloro-N2-[2-isopropoxy-5-methyl-4-(4-piperidinyl)phenyl]-N4-[2-(isopropylsulfonyl)phenyl]-2,4-pyrimidinediamine (ceritinib), (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (lorlatinib; PF-06463922),
- drug active substance
- active ingredient active ingredient
- active agent active agent
- agent agents that are to be understood as meaning a compound in free form or in the form of a pharmaceutically acceptable salt, in particular compounds specified herein.
- an ALK inhibitor is also referred to as “combination partner (i)”.
- SHP2 inhibitor is also referred to as “combination partner (ii)
- joint therapeutically effective amount means the amount at which the therapeutic agents, when given separately (in a chronologically staggered manner, especially a sequence-specific manner) to a warm-blooded animal, especially to a human to be treated, show a (additive, but preferably synergistic) interaction (joint therapeutic effect). Whether this is the case can be determined inter alia by following the blood levels, showing that both compounds are present in the blood of the human to be treated at least during certain time intervals.
- a pharmaceutical combination comprising:
- SHP2 inhibitor is (S)-N-(3-((3-amino-5-(4-amino-2-oxa-8-azaspiro[4.5]decan-8-yl)pyrazin-2-yl)thio)-2-chlorophenyl)-2-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-3-carboxamide.
- a pharmaceutical composition comprising a pharmaceutical combination of any one of Embodiments 1 to 60 and at least one pharmaceutically acceptable carrier.
- salt or “salts” is understood to be a salt of an ALK inhibitor and are preferably pharmaceutically acceptable salts.
- Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like. Since a SHP2 inhibitor may include more than one acidic or basic moieties, the SHP2 inhibitor may include mono, di or tri-salts in a single active ingredient.
- Suitable pharmaceutical compositions for the combination therapy for enteral or parenteral administration are, for example, those in unit dosage forms, such as coated tablets, tablets, capsules or suppositories, or ampoules. If not indicated otherwise, these are prepared in a manner known per se, for example by means of various conventional mixing, comminution, direct compression, granulating, coating, dissolving, lyophilizing processes, or fabrication techniques readily apparent to those skilled in the art. It will be appreciated that the unit content of a combination partner contained in an individual dose of each dosage form need not in itself constitute an effective amount since the necessary effective amount may be reached by administration of a plurality of dosage units, or the therapeutic effect may be achieved only after both combination partners are administered to the subject.
- a therapeutically effective amount of a SHP2 inhibitor in vivo may range depending on the route of administration, between about 0.05 to about 15 mg per kg body weight per day, preferably about 0.1-5 mg/kg/day, more preferably from about 0.25-3 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to a preferable dosage range of about 17.5-210 mg per day.
- each of the combination partners employed in the COMBINATION OF THE INVENTION may vary depending on the particular compound or pharmaceutical composition employed, the mode of administration, the condition being treated, and the severity of the condition being treated.
- the dosage regimen of the COMBINATION OF THE INVENTION is selected in accordance with a variety of factors including the route of administration and the renal and hepatic function of the patient.
- a clinician or physician of ordinary skill can readily determine and prescribe the effective amount of the single therapeutic agents required to alleviate, counter or arrest the progress of the condition.
- each combination partner for treatment of a proliferative disease can be determined empirically for each individual using known methods and will depend upon a variety of factors, including, though not limited to, the degree of advancement of the disease; the age, body weight, general health, gender and diet of the individual; the time and route of administration; and other medications the individual is taking.
- Frequency of dosage may vary depending on the compound used and the particular condition to be treated or prevented. Patients may generally be monitored for therapeutic effectiveness using assays suitable for the condition being treated or prevented, which will be familiar to those of ordinary skill in the art.
- a pharmaceutical preparation comprising:
- the combination of the invention may provide a synergistic therapeutic effect, e.g. with regard to alleviating, delaying progression of or inhibiting the symptoms of proliferative diseases, such as cancer, particularly lung cancer.
- Certain combinations of the invention may provide an additive effect, e.g. with regard to alleviating, delaying progression of or inhibiting the symptoms of proliferative diseases, such as cancer, particularly lung cancer.
- Another aspect of the present invention particularly pertains to a pharmaceutical combination
- a pharmaceutical combination comprising:
- ALK-positive cancer selected from anaplastic large-cell lymphoma, gastric cancer, breast cancers, oesophageal cancer, colorectal cancer, neuroblastoma, inflammatory myofibroblastic tumor, renal cancer, pancreatic cancer and lung cancer.
- a method for treating cancer, in a subject in need thereof, comprising the simultaneous or sequential administration to said subject a therapeutically effective amount of:
- An aspect of the present invention relates to pharmaceutical combinations or pharmaceutical compositions comprising:
- Embodiment 92 wherein the cancer is an ALK-positive cancer.
- Embodiment 92 wherein the cancer is an ALK-positive cancer selected from anaplastic large-cell lymphoma, gastric cancer, breast cancers, oesophageal cancer, colorectal cancer, neuroblastoma, inflammatory myofibroblastic tumor, renal cancer, pancreatic cancer and lung cancer.
- ALK-positive cancer selected from anaplastic large-cell lymphoma, gastric cancer, breast cancers, oesophageal cancer, colorectal cancer, neuroblastoma, inflammatory myofibroblastic tumor, renal cancer, pancreatic cancer and lung cancer.
- Embodiment 92 wherein the cancer is an ALK-positive cancer resistant to the ALK inhibitor of the pharmaceutical combination.
- a commercial package comprising the pharmaceutical combination of any one of Embodiments 1 to 60, together with instructions for simultaneous or sequential administration thereof for use in the treatment of cancer.
- Embodiment 100 wherein the cancer is an ALK-positive cancer resistant to the ALK inhibitor of the pharmaceutical combination.
- Cell colony formation assays were used to assess cell viability and proliferation after compound treatments.
- Cells were plated into 6-well tissue culture plates (6 ⁇ 10 5 cells/well) in a total volume of 2 mL. After 24 hours, compounds were added to the plates. At the end points of the assays, cells were fixed, stained with crystal violet and photographed.
- FIG. 1 shows the photographs obtained from cell colony formation assays with MGH049, MGH045-2A and MGH073-2B cells used to assess the anti-proliferative effect of ceritinib in combination with a SHP2 inhibitor (Compound No. 1).
- Cells were exposed to ceritinib, Compound No. 1 or the combination for 14 days, and stained with crystal violet.
- the combination of ALK and SHP2 inhibition led to significant inhibition of cell survival compared with ceritinib alone.
- Compound No. 1 had no effect on cell growth as a single agent, suggesting that these cell lines are ALK-dependent and signaling via SHP2 functions as a survival pathway or confers resistance to ceritinib.
- combination of ALK and SHP2 inhibition may either enhance the anti-tumor activity of an ALK inhibitor, particularly ceritinib, and/or overcome ALK inhibitor resistance, particularly ceritinib resistance in ALK-positive cancer, such as NSCLC.
- MGH049 and MGH045-2A tumor xenograft models were used to evaluate the efficacy of the combination of an ALK inhibitor with a SHP2 inhibitor in vivo. All animal studies were conducted in accordance with the guidelines as published in the Guide for the Care and Use of Laboratory Animals and Novartis International Animal Care and Use Committee (IACUC) regulations and guidelines.
- the MGH045-2A cells were harvested during exponential growth. Each athymic female nude mouse (Harlan Laboratories, Indianapolis, Ind.) was inoculated subcutaneously in the upper right flank with 5 ⁇ 10 6 NB-1 cells suspended in 0.2 mL cold PBS. The development of MGH049 xenograft tumors comprised 2 steps.
- FIG. 2 demonstrates that in the MGH049 tumor xenograft model the combination of ceritinib and a SHP2 inhibitor (Compound No. 1) was more effective in the inhibition of tumor growth than either compound alone.
- FIG. 3 demonstrates that in the MGH045-2A tumor xenograft model the combination of ceritinib and a SHP2 inhibitor (Compound No. 1) was more effective in the inhibition of tumor growth than either compound alone.
- FIG. 4 demonstrates that in the MGH073-B tumor xenograft model the combination of ceritinib and a SHP2 inhibitor (Compound No. 1) was more effective in the inhibition of tumor growth than either compound alone.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/475,982 US20190343836A1 (en) | 2017-01-10 | 2018-01-08 | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762444493P | 2017-01-10 | 2017-01-10 | |
PCT/IB2018/050111 WO2018130928A1 (en) | 2017-01-10 | 2018-01-08 | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
US16/475,982 US20190343836A1 (en) | 2017-01-10 | 2018-01-08 | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2018/050111 A-371-Of-International WO2018130928A1 (en) | 2017-01-10 | 2018-01-08 | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/714,996 Continuation US20220241277A1 (en) | 2017-01-10 | 2022-04-06 | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190343836A1 true US20190343836A1 (en) | 2019-11-14 |
Family
ID=61028108
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/475,982 Abandoned US20190343836A1 (en) | 2017-01-10 | 2018-01-08 | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
US17/714,996 Pending US20220241277A1 (en) | 2017-01-10 | 2022-04-06 | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/714,996 Pending US20220241277A1 (en) | 2017-01-10 | 2022-04-06 | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
Country Status (11)
Country | Link |
---|---|
US (2) | US20190343836A1 (ru) |
EP (1) | EP3568204B1 (ru) |
JP (2) | JP2020504136A (ru) |
KR (1) | KR102571130B1 (ru) |
CN (1) | CN110730678B (ru) |
AU (1) | AU2018207464B2 (ru) |
CA (1) | CA3048340A1 (ru) |
ES (1) | ES2964956T3 (ru) |
IL (1) | IL267617A (ru) |
RU (1) | RU2769132C2 (ru) |
WO (1) | WO2018130928A1 (ru) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10894797B2 (en) | 2018-09-18 | 2021-01-19 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors |
WO2022235815A1 (en) * | 2021-05-05 | 2022-11-10 | Huabio International, Llc | Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors |
US11827644B2 (en) | 2019-03-04 | 2023-11-28 | Suzhou Genhouse Pharmaceutical Co., Ltd | Pyrazine derivative and application thereof in inhibiting SHP2 |
EP4093406A4 (en) * | 2020-01-24 | 2024-02-28 | Taiho Pharmaceutical Co Ltd | IMPROVEMENT OF THE ANTITUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NEW ANTI-CANCER DRUGS IN CANCER |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
MA43807A (fr) | 2016-03-04 | 2018-11-28 | Taiho Pharmaceutical Co Ltd | Préparation et composition de traitement de tumeurs malignes |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
CA3026784A1 (en) * | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic pyrazine derivatives useful as shp2 inhibitors |
MX2018015625A (es) | 2016-06-14 | 2019-03-06 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de shp2. |
SG11201900157RA (en) | 2016-07-12 | 2019-02-27 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
JP7240319B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ,インコーポレイテッド | アロステリックshp2阻害剤としての二環式化合物 |
EP3571189B1 (en) | 2017-01-23 | 2023-03-29 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
WO2019051084A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER |
US10435389B2 (en) | 2017-09-11 | 2019-10-08 | Krouzon Pharmaccuticals, Inc. | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2 |
WO2019075265A1 (en) * | 2017-10-12 | 2019-04-18 | Revolution Medicines, Inc. | PYRIDINE, PYRAZINE AND TRIAZINE COMPOUNDS AS ALLOSTERIC INHIBITORS OF SHP2 |
MX2020006273A (es) | 2017-12-15 | 2020-09-14 | Revolution Medicines Inc | Compuestos policiclicos como inhibidores alostericos de shp2. |
SG11202006778TA (en) | 2018-03-02 | 2020-08-28 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
EP3769765B1 (en) | 2018-03-19 | 2024-04-17 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
US10561655B2 (en) | 2018-03-21 | 2020-02-18 | Synblia Therapeutics, Inc. | SHP2 inhibitors and uses thereof |
MX2020011528A (es) | 2018-05-02 | 2021-02-09 | Navire Pharma Inc | Inhibidores heterociclicos sustituidos de ptpn11. |
EA202190342A1 (ru) * | 2018-07-24 | 2021-07-22 | Тайхо Фармасьютикал Ко., Лтд. | Гетеробициклические соединения для ингибирования активности shp2 |
EP4356973A2 (en) | 2018-08-10 | 2024-04-24 | Navire Pharma, Inc. | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
CN112867718A (zh) | 2018-09-29 | 2021-05-28 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物的制造 |
WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
CN111153899B (zh) * | 2018-11-08 | 2023-12-01 | 四川科伦博泰生物医药股份有限公司 | 一种取代吡啶化合物、其制备方法和用途 |
BR112021009880A2 (pt) | 2018-11-30 | 2021-08-17 | Tuojie Biotech (Shanghai) Co., Ltd. | pirimidina e derivado de heterociclo de nitrogênio de cinco membros, método de preparação para os mesmos e usos médicos dos mesmos |
US20220160707A1 (en) * | 2019-02-12 | 2022-05-26 | Novartis Ag | Pharmaceutical combination comprising tno155 and ribociclib |
EP3924053A1 (en) * | 2019-02-12 | 2021-12-22 | Novartis AG | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
AU2020222295B2 (en) * | 2019-02-12 | 2023-04-06 | Novartis Ag | Pharmaceutical combination comprising TNO155 and a PD-1 inhibitor |
WO2020180770A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
CN113767100A (zh) | 2019-03-01 | 2021-12-07 | 锐新医药公司 | 双环杂芳基化合物及其用途 |
JP2022524759A (ja) | 2019-03-07 | 2022-05-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Shp2アンタゴニストとしてのカルボキサミド-ピリミジン誘導体 |
CN113646049A (zh) | 2019-04-08 | 2021-11-12 | 默克专利有限公司 | 作为shp2拮抗剂的嘧啶酮衍生物 |
US20220380385A1 (en) | 2019-06-28 | 2022-12-01 | Tuojie Biotech(Shanghai) Co., Ltd. | Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof |
CN114502165A (zh) * | 2019-09-23 | 2022-05-13 | 苏州浦合医药科技有限公司 | Shp2抑制剂及其用途 |
CN112724145A (zh) * | 2019-10-14 | 2021-04-30 | 杭州雷索药业有限公司 | 用于抑制shp2活性的吡嗪衍生物 |
JP2022553859A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ras阻害剤 |
TW202132315A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras 抑制劑 |
BR112022008565A2 (pt) | 2019-11-04 | 2022-08-09 | Revolution Medicines Inc | Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras |
CN114901662A (zh) | 2019-11-08 | 2022-08-12 | 锐新医药公司 | 双环杂芳基化合物及其用途 |
CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
WO2021110796A1 (en) * | 2019-12-04 | 2021-06-10 | Bayer Aktiengesellschaft | Inhibitors of shp2 |
CN113135910A (zh) * | 2020-01-19 | 2021-07-20 | 北京诺诚健华医药科技有限公司 | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 |
CN111265529B (zh) * | 2020-02-22 | 2021-07-23 | 南京大学 | 蛋白酪氨酸磷酸酶shp2抑制剂在制备治疗银屑病药物中的应用 |
CN111393459B (zh) * | 2020-04-16 | 2022-07-22 | 南京安纳康生物科技有限公司 | Shp2抑制剂及其用途 |
KR20230008719A (ko) * | 2020-05-08 | 2023-01-16 | 노파르티스 아게 | Tno155 및 나자르티닙을 포함하는 약제학적 조합물 |
US20230218765A1 (en) * | 2020-05-19 | 2023-07-13 | The Regents Of The University Of Michigan | Small molecule degraders of shp2 protein |
IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
EP4214209A1 (en) | 2020-09-15 | 2023-07-26 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
CN114437116A (zh) * | 2020-10-30 | 2022-05-06 | 赣江新区博瑞创新医药有限公司 | 杂环化合物及其制备方法、药物组合物和应用 |
CN112194652B (zh) * | 2020-11-30 | 2021-03-05 | 北京华氏开元医药科技有限公司 | 4-羟甲基-1h-吲哚类化合物、制备方法及应用 |
CN112402385B (zh) * | 2020-11-30 | 2022-04-01 | 北京华氏开元医药科技有限公司 | 4-羟甲基-1h-吲哚类化合物药物制剂及其制备方法 |
AR124449A1 (es) | 2020-12-22 | 2023-03-29 | Qilu Regor Therapeutics Inc | Inhibidores de sos1 y usos de los mismos |
CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
EP4334321A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Ras inhibitors |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
EP4368614A1 (en) * | 2021-07-07 | 2024-05-15 | Hinova Pharmaceuticals Inc. | Synthesis and application of phosphatase degrader |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
KR20230106506A (ko) * | 2022-01-03 | 2023-07-13 | 한국생명공학연구원 | Cda 억제제를 포함하는 alk 저해제 내성 비소세포폐암 치료용 조성물 |
TW202342040A (zh) | 2022-02-21 | 2023-11-01 | 瑞士商諾華公司 | 藥物配製物 |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5208123B2 (ja) | 2006-12-08 | 2013-06-12 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
NZ703124A (en) * | 2012-05-23 | 2016-07-29 | Nerviano Medical Sciences Srl | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
RU2016129953A (ru) * | 2013-12-23 | 2018-01-30 | Новартис Аг | Фармацевтические комбинации |
ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
US9815813B2 (en) | 2014-01-17 | 2017-11-14 | Novartis Ag | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 |
CA2955676A1 (en) * | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
US9296721B1 (en) * | 2015-02-13 | 2016-03-29 | Yong Xu | Method for preparing ALK inhibitor ceritinib |
CN112625028A (zh) * | 2015-06-19 | 2021-04-09 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
EP3310771B1 (en) * | 2015-06-19 | 2020-07-22 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
ES2741746T3 (es) * | 2015-06-19 | 2020-02-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
WO2017156397A1 (en) * | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
EP3515916B1 (en) * | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
TW201819386A (zh) * | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
-
2018
- 2018-01-08 WO PCT/IB2018/050111 patent/WO2018130928A1/en active Application Filing
- 2018-01-08 KR KR1020197019305A patent/KR102571130B1/ko active IP Right Grant
- 2018-01-08 JP JP2019536863A patent/JP2020504136A/ja active Pending
- 2018-01-08 US US16/475,982 patent/US20190343836A1/en not_active Abandoned
- 2018-01-08 ES ES18701574T patent/ES2964956T3/es active Active
- 2018-01-08 EP EP18701574.8A patent/EP3568204B1/en active Active
- 2018-01-08 CN CN201880006104.XA patent/CN110730678B/zh active Active
- 2018-01-08 CA CA3048340A patent/CA3048340A1/en active Pending
- 2018-01-08 RU RU2019120986A patent/RU2769132C2/ru active
- 2018-01-08 AU AU2018207464A patent/AU2018207464B2/en active Active
-
2019
- 2019-06-24 IL IL267617A patent/IL267617A/en unknown
-
2022
- 2022-04-06 US US17/714,996 patent/US20220241277A1/en active Pending
- 2022-09-07 JP JP2022142153A patent/JP2022184886A/ja active Pending
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10894797B2 (en) | 2018-09-18 | 2021-01-19 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors |
US11034705B2 (en) | 2018-09-18 | 2021-06-15 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors |
US11459340B2 (en) | 2018-09-18 | 2022-10-04 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors |
US11518772B2 (en) | 2018-09-18 | 2022-12-06 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors |
US11827644B2 (en) | 2019-03-04 | 2023-11-28 | Suzhou Genhouse Pharmaceutical Co., Ltd | Pyrazine derivative and application thereof in inhibiting SHP2 |
EP4093406A4 (en) * | 2020-01-24 | 2024-02-28 | Taiho Pharmaceutical Co Ltd | IMPROVEMENT OF THE ANTITUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NEW ANTI-CANCER DRUGS IN CANCER |
WO2022235815A1 (en) * | 2021-05-05 | 2022-11-10 | Huabio International, Llc | Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
KR20190104530A (ko) | 2019-09-10 |
RU2769132C2 (ru) | 2022-03-28 |
CN110730678A (zh) | 2020-01-24 |
AU2018207464B2 (en) | 2020-05-14 |
JP2020504136A (ja) | 2020-02-06 |
CA3048340A1 (en) | 2018-07-19 |
IL267617A (en) | 2019-08-29 |
RU2019120986A3 (ru) | 2021-03-19 |
CN110730678B (zh) | 2022-07-15 |
EP3568204B1 (en) | 2023-08-30 |
KR102571130B1 (ko) | 2023-08-28 |
US20220241277A1 (en) | 2022-08-04 |
RU2019120986A (ru) | 2021-02-12 |
WO2018130928A1 (en) | 2018-07-19 |
AU2018207464A1 (en) | 2019-06-20 |
EP3568204A1 (en) | 2019-11-20 |
JP2022184886A (ja) | 2022-12-13 |
ES2964956T3 (es) | 2024-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220241277A1 (en) | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor | |
US10130629B2 (en) | Pharmaceutical combinations | |
US20230151014A1 (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | |
JP6863970B2 (ja) | ヘテロ環式化合物およびそれらの使用 | |
US9695200B2 (en) | Heterocyclic ITK inhibitors for treating inflammation and cancer | |
US20190134033A1 (en) | Pharmaceutical combinations | |
US20230158022A1 (en) | Methods of using myt1 inhibitors | |
US20160074409A1 (en) | Treatment of Skeletal-Related Disorders | |
US20210277002A1 (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
UA125216C2 (uk) | Комбінована терапія | |
US20110065712A1 (en) | Tricyclic compounds and pharmaceutical uses thereof | |
EA017952B1 (ru) | ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ | |
US20230122909A1 (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | |
CA3148278A1 (en) | Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors | |
US20140142129A1 (en) | Methods of treating a disease or disorder associated with bruton's tyrosine kinase | |
EP2177222B1 (en) | Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis | |
RU2445960C2 (ru) | Применение производных пиримидиламинобензамида для лечения системного мастоцитоза | |
WO2021100677A1 (ja) | 併用医薬 | |
RU2806857C2 (ru) | Соединения, фармацевтические композиции, способы приготовления соединений и их применение в качестве ингибиторов киназы atr |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALGHALANDIS, LEILA DARDAEI;REEL/FRAME:050962/0798 Effective date: 20171222 Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.;REEL/FRAME:050962/0793 Effective date: 20171211 Owner name: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAO, HUAIXIANG;LAMARCHE, MATTHEW J.;WANG, HUI-QIN;REEL/FRAME:050962/0760 Effective date: 20171205 Owner name: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ENGELMAN, JEFFREY ADAM;REEL/FRAME:050962/0804 Effective date: 20181206 Owner name: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LI, FANG;REEL/FRAME:050962/0779 Effective date: 20170126 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |